Korean J Anesthesiol.  2011 Aug;61(2):127-132. 10.4097/kjae.2011.61.2.127.

The proper effect site concentration of remifentanil for prevention of myoclonus after etomidate injection

Affiliations
  • 1Department of Anesthesiology and Pain Medicine, Pusan National University School of Medicine, Yangsan, Korea. shinsw@pusan.ac.kr

Abstract

BACKGROUND
Etomidate frequently induces myoclonus when administered intravenously with bolus injection during anesthetic induction. This can be bothersome for the anesthesiologist. The dose of remifentanil appropriate for preventing myoclonus without side effects was investigated.
METHODS
All patients with American Society of Anesthesiologists (ASA) physical status I-III were divided into three groups (n = 33 per group) according to the pretreatment effect site concentration of remifentanil (Ultiva, Glaxo-Wellcome, Munchen, Germany) of 0, 2 or 4 ng/ml (Group N: 0 ng/ml, Group R: 2 ng/ml, Group Q: 4 ng/ml) by a target controlled infusion (TCI) system. After a 0.3 mg/kg dose of etomidate was injected intravenously for over 1 minute for anesthetic induction, myoclonus was observed. Before the etomidate injection, the patients were pretreated with remifentanil and their side effects were monitored.
RESULTS
The number of patients showing myoclonus was significantly different among the groups. The incidence of myoclonus was 81%, 12% and 0% (groups N, R, and Q, respectively, P < 0.01). Side effects including bradycardia and hypotension did not occur in either Group R or Q. Chest wall rigidity occured in 45% of patients in Group Q.
CONCLUSIONS
Administration with a 2 ng/ml effect site concentration of remifentanil could reduce the incidence of myoclonus caused by etomidate bolus injection without chest wall rigidity.

Keyword

Etomidate; Myoclonus; Remifentanil

MeSH Terms

Bradycardia
Etomidate
Humans
Hypotension
Incidence
Myoclonus
Piperidines
Thoracic Wall
Etomidate
Piperidines
Full Text Links
  • KJAE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr